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Abstract 
Synthetic biology is in the process of inventing itself and its ownership regimes. There 
are currently two dominant approaches to ownership and sharing in the field. The work 
of the J. Craig Venter Institute is grounded in molecular biology and in gene patenting. 
Parts-based approaches to synthetic biology, in contrast, are inspired by engineering, 
open source software and distributed innovation, and they are building new 
communities to help further this agenda. Despite these differences, the two approaches 
make very similar use of informational and computational metaphors. They both also 
have a place in a vision for the future of synthetic biology as a ‘diverse ecology’ of the 
open and the proprietary. It remains to be seen whether such a diverse ecology will be 
sustainable, whether synthetic biology will go down the patenting route taken by 
previous biotechnologies, or whether different forms of ownership and sharing will 
emerge. Which path is taken will depend on the success of synthetic biology in achieving 
both its technical objectives and its social innovations.  
 
Keywords: synthetic biology; intellectual property; open source; distributed innovation; 
informational metaphors 
 
 
Introduction 
A cursory look at the field of synthetic biology reveals two dominant approaches to 
intellectual property (IP). On the one hand, there is the work of the J. Craig Venter 
Institute (JCVI), which is grounded in molecular biology, and has a long tradition of filing 
patents. On the other hand, there are engineering-oriented parts-based approaches to 
synthetic biology, which draw their inspiration from open source software. In this paper 
I show how the IP approach of the JCVI can be seen as a continuation of gene patenting, 
while parts-based synthetic biology draws on a different tradition of distributed 
innovation. Crudely put, the contrast is between the proprietary and the open, although, 
as we will see, the situation is in reality more complicated. 
 
There are other approaches to synthetic biology of course (see O’Malley et al, 2008), 
stretching from the creation of alternative genetic alphabets (Pollack, 2001), to attempts 
to recreate the conditions under which life originated in the universe (Luisi et al, 2006). 
But the two approaches I focus on here have the most relevance for IP debates. It is 
significant that they both also make particularly striking use of informational and 
computational metaphors. For example, Venter talks about ‘booting up’ a cell with a 
synthetic genome, and proponents of parts-based approaches emphasise the inter-
convertability of genetic information and material, enabled by DNA sequencing and 
synthesis technologies. The same metaphors are used for very different purposes, 
however. While the JCVI uses them to extend their proprietary claims, parts-based 
approaches engage in explicit attempts to introduce norms of openness and sharing into 
the field.  
 
It is important not to overemphasise the differences between these two approaches, 
however, since both have to grapple with context-dependent and recalcitrant biological 
systems. Furthermore, the attempt to develop a bespoke ownership regime for standard 
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biological parts explicitly aims to foster a ‘diverse ecology’ of the open and the 
proprietary. 
 
This paper draws on five years of engagement with the emerging field of synthetic 
biology as a participant observer in a range of different sites in Europe and the US, 
including attendance at numerous workshops, conferences and meetings. I also draw on 
the scientific literature in synthetic biology, as well as policy reports and grey literature. 
The extent to which social scientists studying synthetic biology can (or should) think of 
themselves as part of the synthetic biology community is an important methodological 
question, but one that extends beyond the scope of this paper. 
 
 
Gene patenting 
 
It is helpful to ground a discussion of IP in synthetic biology in the much longer running 
practice of gene patenting. There is a wealth of literature on gene patenting that I will 
not rehearse here.1 For the purposes of this paper, what is particularly interesting is 
how genes came to be thought of as carriers of information in patent contexts. Kay 
(2000) shows how the introduction of informational metaphors such as the ‘genetic 
code’ into the biological sciences should be understood as part of a broader shift to 
informational thinking in many fields in the late 1940s and early 1950s. Informational 
metaphors became extremely influential in molecular genetics, which blossomed after 
the discovery of DNA in 1953 (Keller, 2000; Moss, 2003).  Dupré (2004) argues that 
molecular genetics changed the representation of the gene from ‘Mendelian’ to 
‘molecular’. A Mendelian gene can be understood as a hypothetical factor that is 
statistically correlated with a phenotypic trait. A molecular gene, in contrast, is usually 
described as a specific stretch of DNA that codes for a particular polypeptide. What is 
important about the move from Mendelian to molecular genes is that it not only 
transformed a gene into a material entity, but also into a carrier of information 
(Rheinberger, 2000).  
 
This material/informational duality of the gene was sidestepped in patent law, however, 
because when genes first started being patented in late 1970s and early 1980s they 
were simply treated as if they were chemical compounds. By this time ‘isolated and 
purified’ naturally occurring chemical compounds could be patented, as long as they 
fulfilled the other requirements for patentability (Conley and Makowski, 2003; Demaine 
and Fellmeth, 2002), so this argument was simply extended to genes, and it led to a 
proliferation of patenting activity around genetic entities (Nuffield Council, 2002). 
 
One infamous example of such activity was an attempt by the US National Institutes of 
Health, led by Craig Venter, to patent thousands of short DNA sequences called 
‘Expressed Sequence Tags’ (or ESTs) in 1991-1992. The patent applicants knew that 
these DNA sequences were expressed, and surmised that they played an important 
biological role, but they did not know what this role was (Cornish et al, 2003). This 
attempt to patent ESTs was ultimately unsuccessful, but it is important because it shows 
the limitations of treating genes as chemical compounds. The reason that the ESTs were 
considered potentially valuable was not because of their chemical nature, but because of 
their potential role as carriers of information (Rai, 1999). 
 
It is well known that Venter was at the centre of the attempt to patent ESTs, but he was 
also behind some other important patents in the 1990s which usually receive much less 
                                                 
1 See for example Conley and Makowski (2003) and Demaine and Fellmeth (2002). 
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attention, although they are particularly relevant to recent proprietary moves in 
synthetic biology. 
 
In the 1990s, the Institute for Genomic Research (now part of the JCVI) sequenced the 
genomes of the scientifically important bacteria Haemophilus influenzae (Fleischmann et 
al, 1995) and Mycoplasma genitalium (Fraser et al, 1995), and the Archaea 
Methanococcus jannaschii (Bult et al, 1996). In each case, a patent was filed on the 
genome sequence before its publication by the affiliated company Human Genome 
Sciences (Shreeve, 2004; O’Malley et al, 2005). What is interesting about these patent 
applications is that, like the earlier ESTs applications, they were based on the 
informational properties of the DNA sequences. These applications went further than 
the ESTs applications however, because all three of them originally claimed the 
complete genome sequence in ‘computer-readable medium’. The patent specifications 
argued that having the genome sequences in such a form would allow them to be used in 
comparative searches against existing DNA databases, and that this would help identify 
parts of the genome with commercial or biological significance. The three applications 
did not survive the examination procedure in this form, however. When they were 
finally granted, the patents claimed specific DNA sequences in a more conventional 
manner (Bostanci and Calvert, 2008). 
 
These applications should be understood in their historical context, where computation 
and bioinformatics were becoming increasingly important in molecular biology (Cook-
Deegan, 1994). Computer software was also becoming patentable in the mid-1990s in 
the US, thanks to a series of court rulings (Bonaccorsi et al, 2011). Although the 
computer-embodied genome patents were ultimately not successful, they are an 
indication of an informational shift in genomics and patenting that was happening at the 
time. The emphasis on the informational importance attributed to the genome is shown 
by the fact that in the original patent applications, the genomes were referred to as the 
“life sustaining instructions and information” of the organism.2 This particular 
understanding of the role of the genome is central to synthetic biology, but it has been 
heavily critiqued by philosophers, scientists and other commentators (see, for example, 
Barnes and Dupré, 2008; Kay, 2000; Keller, 2000; Moss, 2003; Sarkar, 1996). This 
literature argues that phenotypic properties of an organism cannot be reduced to the 
properties of its genes, because organismal properties are context-dependent and 
emerge at higher levels of organisation.  
 
Patent law avoided these discussions, however, by persisting in treating genes as if they 
were merely chemical compounds, until recent developments re-invigorated the debate 
(Calvert and Joly, 2011). In April 2010 the patent world was shocked by Judge Sweet’s 
ruling at the United States District Court for the Southern District of New York which 
invalidated patents owned by the company Myriad Genetics that test for breast cancer 
susceptibility genes (Association for Molecular Pathology et al v. USPTO et al, 2010). The 
ruling is based on exactly the same argument made by Rheinberger (2000) above, that 
genes are both informational and material: 
 
Genes are of double nature: on the one hand, they are chemical substances 
or molecules. On the other hand, they are physical carriers of information, 
i.e., where the actual function of this information is coding for proteins. 
(Association for Molecular Pathology et al v. USPTO et al, 2010: 7) 
 
The decision goes on to argue that this informational quality is unique among chemical 
compounds, and that since this quality is the same for the gene in isolated and purified 
                                                 
2 USPTO Applications Nos. 08/476,102 and 08/545,528. 
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form as it is in nature, genes constitute unpatentable subject matter. This decision has 
been appealed and may be reversed,3 but what I want to draw attention to here are the 
divergent conclusions that can be drawn from the notion that genes are “the physical 
embodiment of biological information” (Association for Molecular Pathology et al v. 
USPTO et al, 2010, p. 3). As noted above, this type of genetic reductionism is heavily 
critiqued for ignoring the contingency and context-specificity of the operation of a gene, 
but in this case, it is precisely because the genetic information is regarded as ‘the same’ 
in two very different contexts (in the body and in the genetic test), that Judge Sweet was 
able to make the argument that the gene should not be patented. Here we see genetic 
reductionism being used to argue against gene patenting. 
 
 
Synthetic genomes 
 
A very similar notion of the informational nature of DNA is found in the JCVI’s recent 
paper ‘Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome’ 
(Gibson et al, 2010). This paper was heralded as a landmark achievement because an 
entirely synthetic version of a natural genome was created and implanted into a 
recipient cell, where it took over the function of that cell and successfully replicated. The 
scientists named the synthesized version of the natural Mycoplasma mycoides bacteria 
‘Mycoplasma mycoides JCVI-syn1.0’ (note the use of the software naming convention). In 
describing this work, Venter talked about how the synthetic genome ‘booted up’ the 
recipient cell (Sample, 2010). He also said that this was “the first cell to have its parent 
be a computer” (Jones, 2010), meaning that the sequence was determined in a computer 
before being synthesized in material form. The published scientific paper reinforces 
these notions by saying that “DNA sequencing of a cellular genome allows storage of the 
genetic instructions for life as a digital file” (Gibson et al, 2010, p. 4, emphasis added). 
And the authors continue this computational metaphor by adding that “the DNA 
software builds its own hardware” (ibid.). 
 
Although this paper received a large amount of media attention, it was a proof-of-
principle experiment, with the longer-term aim of developing a simplified synthetic 
minimal genome, with all non-essential genes deleted. This is where Venter’s earlier 
work, discussed above, becomes relevant. One of the genomes that The Institute for 
Genomic Research chose to sequence (and patent) in the mid-1990s was the bacteria 
Mycoplasma genitalium. This organism was chosen because it has one of the smallest 
known natural genomes, being an obligate parasite which is dependent on its host for 
many essential nutrients. It provided the ideal starting point for work on constructing a 
streamlined, minimal genome. 
 
Venter is notorious for vigorously pursuing IP rights, as demonstrated by the ESTs 
episode described above, so it is not surprising that his group has already filed several 
patents relating to this recent work. The most controversial is an application filed in May 
2007 for the smallest genome needed for a living organism (Glass et al, 2007).4 The 
patent application, simply entitled ‘Minimal bacterial genome’, starts its first claim with 
                                                 
3 In fact, this decision was overruled in July 2011 in the Court of Appeals for the Federal Circuit 
(CAFC). Interestingly, the idea that DNA is chemical (rather than informational) and that it can be 
reduced to its chemical nature was assumed by one of the CAFC judges, who argued that merely 
detaching a segment of DNA from its natural context gives it a different chemical identity. The 
American Civil Liberties Union will be pursuing Myriad in the Supreme Court (Allsup, 2011). 
4 Other important method applications that I do not have space to discuss here are Venter et al 
(2007) ‘Synthetic genomes’ (application number 11/635,355, filed in 2006), and Gibson et al 
(2009) ‘Assembly of large nucleic acids’ (application number 12/247,126, filed in 2008). 
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“A set of protein-coding genes that provides the information required for growth and 
replication of a free living organism…” (emphasis added). In this patent application, as in 
previous whole-genome applications from this group, as well as in their recent paper, 
we see again the idea that genes provide the crucial “instructions for life”. In contrast to 
the Myriad case, however, this understanding of genes is used to argue that they are the 
legitimate target of patent applications.  
 
The group hopes that its simplified cellular ‘chassis’ will be used to build new life forms 
that perform useful functions (such as develop biofuels), and it is for this reason that the 
patent application specifically claims the use of the minimal cell for hydrogen or ethanol 
production. This has led some groups to worry that such claims could potentially lead to 
the dominance of one particular chassis, allowing the Venter Institute to become the 
‘Microbesoft’ of synthetic biology (ETC Group, 2007). But we should not forget that this 
patent is still at the application stage, and many commentators think it has little chance 
of being granted (Nature Biotechnology, 2007). 
 
The attempt to assert ownership over biology entities is of course not unique to the JCVI, 
or to synthetic biology, but it is part of a much broader movement to transform living 
substances into marketable products, a movement which has been the focus of recent 
literature on ‘biocapital’ (see, for example, Helmreich, 2008; Rose, 2006; Sunder Rajan, 
2006). This work shows how developments in the biosciences have allowed things such 
as microbes, cells and genes to become commodities (Rahaman, 2011). For something to 
be a commodity it must be mobile, and detachable from its original context (Callon, 
1998). Rose (2007) describes this as a ‘flattened’ world, where “almost any vital element 
can, in principle, be freed from its ties to cell, organ, organism, or species, set free to 
circulate and to be combined with any other” (p.16). It is only when the world is 
‘flattened’ in this way that biological entities emerge as things that can be owned.  These 
arguments resonate with the literature discussed above that is critical of genetic 
reductionism, which suggests that this flattened world provides an impoverished 
understanding of living things. 
 
Bearing this in mind, it is notable that the striking genetic reductionism of both the 2007 
minimal genome patent application and the JCVI’s 2010 paper are weakened on further 
reading. The patent application states upfront that the minimal bacterial genome is 
dependent on a “rich bacterial culture medium”, and in the patent description there is 
talk of implanting the genome into an enucleated ‘ghost cell’ which already has a 
membrane, ribosomes, and nucleic acid replication machinery.5 Similarly, in the 2010 
paper we are told that the synthetic genome will only thrive if it is implanted into an 
existing cell. It could be concluded that the recipient cell is a crucially important part of 
the new ‘synthetic cell’ – that context matters.  
 
 
Biology as engineering 
 
The JCVI’s work shows the continuities between gene patenting and IP in synthetic 
biology, but the parts-based approach aspires to develop different ways of owning and 
sharing biological systems, by attempting to transpose the normative values associated 
with open innovation regimes into the nascent synthetic biology community. 
 
A definition of the parts-based approach to synthetic biology is “the design and 
construction of new biological parts, devices, and systems and the re-design of existing, 
                                                 
5 In fact, they did not have to use such a ghost cell in their work; instead they manipulated the 
methylation patterns and restriction systems of the host and donor DNA (Gibson et al, 2010). 
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natural biological systems for useful purposes”.6 The distinction made here between 
‘parts’, ‘devices’ and ‘systems’ is the first indication that this approach is heavily 
influenced by engineering. In fact, one of the most conceptually interesting aspirations 
of this school is to make biology into an engineering discipline (Brent, 2004). 
 
The guiding aim of this approach is to develop biological components which are 
standardized, interchangeable and can be combined (often called ‘BioBricks’), so that 
new parts do not have to be created in a bespoke manner every time a new biological 
device is built. In the context of IP, the most important principle adopted by this 
approach to synthetic biology is modularity. Modularity is not a straightforward 
concept, but in engineering terms it is defined as a functional unit that maintains its 
properties irrespective of what it is connected to (Sauro, 2008). A clear demonstration 
of the modular approach in synthetic biology is the Registry of Standard Biological Parts, 
a website where information on BioBricks can be downloaded.7 
 
There is much discussion in synthetic biology over whether biological systems are 
actually made of functional modules (Arkin and Fletcher, 2006), or whether they are 
simply best understood as if they are by the engineering approaches that are adopted in 
synthetic biology (Morange, 2009). Some argue that modules are favoured by natural 
selection, since they can evolve independently of each other (Hartwell et al, 1999; Sauro, 
2008), while others disagree (Lynch, 2007).  There is no consensus on this issue, but 
whether or not biological systems are actually modular, the question that arises is, can 
they be made to be so? This is a question that currently guides much work in synthetic 
biology (Chin, 2006).  
 
As Pottage (2009) has noted, modular systems are well suited to IP regimes, since 
“property lawyers of all species are quite at home with the notion of modularity” 
(p.169). This is because modular entities are discrete, which makes them easier to 
describe in patents and to treat as commodities. We see that in applying engineering 
principles to biology, synthetic biology is making biology better fit with IP regimes 
(Calvert, 2008). This is not a coincidence because patent law itself developed in the 
context of industrial manufacturing (Pottage and Sherman, 2007), which synthetic 
biology models itself upon. 
 
What is particularly interesting about modularity is that it not only lends itself to 
conventional forms of IP such as patents, but it also “opens novel ways of imagining the 
organization of collaborative production” (Pottage, 2009, p. 170). Modular entities are 
well-suited to commons-based regimes such as open source, because dispersed 
individuals can work on different modules simultaneously, and they do not have to be 
highly incentivised to make minor modifications (Benkler, 2002). So we see that 
commons-based production and private appropriation rely on the very same 
characteristics. 
 
 
                                                 
6 See http://www.syntheticbiology.org/ 
7 See http://partsregistry.org/ 
 7
Ownership and sharing of BioBricks 
 
As with the JCVI’s work on synthetic genomes, computational and informational 
metaphors are central to the BioBricks strand of synthetic biology.  For example, 
synthetic biologists talk about how DNA can be ‘decompiled’ through sequencing and 
then ‘recompiled’ through synthesis (Specter, 2009), perhaps even ‘refactored’ (Chan et 
al,  2005). There is also discussion of how “DNA sequencing and synthesis technologies 
make genetic information and material interconvertible” (Endy, 2009, p.7). And it is the 
ideal of de-contextualised genetic information that synthetic biologists have in mind 
when they talk about how in the future the transfer of information will be all that will be 
needed to reproduce biological systems, meaning that transaction costs will become 
minimal (Carlson, 2010).   
 
The parallels that are drawn to software in the BioBricks field are perhaps not 
surprising considering that several founders of the BioBricks approach have their 
origins in the computer industry. Tom Knight, the ‘father’ of this approach, is a computer 
scientist who was heavily involved in ARPANET (the Advanced Research Projects 
Agency Network). Randy Rettberg, who is responsible for the iGEM competition 
(discussed below) had a previous career at Sun Microsystems (Robbins, 2009). The 
central role of these key individuals helps explain why software is a common reference 
point, and why modularity is an important aspiration of the field. The hope is that in the 
future biological parts will be combined “in the same manner that Linux modules are 
now combined to make software” (Maurer, 2009, p. 806). As this reference to Linux 
suggests, open source is an important aspiration. In fact, when the field was being 
named in the late 1990s one suggestion was to call it ‘open source biology’ (Carlson, 
2010), partially because early synthetic biology seemed to have some of “the scruffy 
hacker ethos that had spurred the personal-computing revolution” (Ledford, 2010, p. 
650). Carlson and Brent (2000) put in an (unsuccessful) application to DARPA for 
funding for ‘open source biology’ in 2000, and in this application they talk about the 
necessity for a “publicly available kernel” (p.2), again adopting the language of software 
operating systems. It is notable that while the JCVI’s computational metaphors and 
emphasis on the informational nature of DNA leads them to attempt to gain private 
ownership of this DNA, similar computational metaphors lead another branch of 
synthetic biologists to advocate something analogous to open source. I will return to this 
point below. 
 
Regular comparisons to Linux and open source software are not sufficient to ensure that 
the BioBricks approach actually does develop along these lines, however. Concerted 
efforts are needed, and this is where we see work being done to establish the 
appropriate norms within the synthetic biology community. For example, the BioBricks 
Foundation has been set up in an attempt to ensure that the information needed to build 
BioBricks is freely available in the public domain. And the BioBrick Public Agreement 
(described below) aims to foster “the open design, construction, distribution, 
understanding, and use of BioBrick™ compatible parts”.8 Introducing such norms of 
openness requires novel forms of community-building.  
 
 
Community building 
 
The most important community-building activity in the BioBricks field is the annual 
International Genetically Engineered Machines competition, or ‘iGEM’ for short. This 
event started in 2003 as an internal competition to MIT, but it has now extended to the 
                                                 
8 http://biobricks.org/bpa/users/agreement/ (emphasis added) 
 8
point where undergraduate teams from different universities across the globe compete 
to build the best ‘genetically engineered machine’, using BioBrick parts. The 2011 
competition involved 165 teams with well over 1000 students taking part.9 What is 
particularly interesting about the competition is that the aim is to build a community 
that not only shares a technical approach, but also shares certain values about safety, 
security and, perhaps most importantly, open access to the technology. Some synthetic 
biologists are quite explicit about the fact that the competition aims to shape “the 
ideology, values and culture of the synthetic biology community” (Smolke, 2009, p. 
1099). Teams are rewarded not only for contributing parts to the Registry, but also for 
‘debugging’ existing parts.10 In this way, a value system is being built into the biological 
parts (Pottage, 2009). Because BioBricks are designed to be standardised and 
interchangeable, by creating and ‘debugging’ BioBricks, iGEM teams are providing parts 
for others to use in the future, and in this way they are embracing the community ethos 
of open access. 
 
iGEM has grown exponentially since 2003, and it has enthused many young people 
about synthetic biology and encouraged them to pursue further work in the field 
(Mitchell et al, 2011). In the context of iGEM’s success, it is perhaps surprising that it 
rests on very shaky IP foundations. Many of the DNA sequences in the Registry are 
already covered by patent claims (Rai, 2009). For example, there is strong IP on Green 
Fluorescent Protein, an important reporter used by almost all the teams (Chalfie and 
Prasher, 1996). If iGEM was a for-profit competition then it would undoubtedly be sued 
for IP infringement. Since it is currently an academic venture (with teams requiring an 
academic institutional affiliation to participate), the incentive for patent holders to 
pursue litigation is limited, but this threat continually hovers in the background, with 
the potential to be fatal to the whole operation (Rettberg, 2009). Although some 
synthetic biologists admit that iGEM is currently breaking the existing IP regime, they do 
not conclude from this that iGEM should modify itself in line with existing requirements, 
but argue instead that this demonstrates that the IP regime itself is broken and needs a 
fundamental overhaul. 
 
The competition is a very important annual event for the BioBricks strand of synthetic 
biology, and it is unusual that an undergraduate competition (which even sometimes 
involves teams from high schools), should assume such prominence in a cutting-edge 
scientific field. But this is part of the ethos of the BioBricks approach to synthetic 
biology, because one of its main objectives is to make biology easy to engineer, and to 
broaden the range of people who can participate in the field. This impulse to broaden 
participation has resulted a second social phenomenon – the Do It Yourself Biology 
movement (DIYbio). Discussions of DIYbio, again, often rest on parallels between 
synthetic biology and open source software (Kelty, 2010). One of the notable features of 
this sector is that the distinction between developers and users is not sharp (Von Hippel, 
2005), so if synthetic biology is becoming more like software engineering (as its 
proponents continually stress), this may explain why users are becoming more involved 
in various different forms of ‘biohacking’. 
 
DIYbio is partially enabled by technological developments which have reduced the cost 
and increased the ease of access to the technologies needed to do synthetic biology, 
particularly DNA synthesis. But more importantly, it represents the aspiration to make 
biology into a technology that is accessible to all (Bobe, 2010). DIYbio itself is a loose 
                                                 
9 See http://igem.org/About 
10 One of the requirements for a Gold Medal in the 2010 iGEM is to “Characterize or improve an 
existing BioBrick Part or Device and enter this information back on the Registry” 
(http://2010.igem.org/Judging/Judging_Criteria). 
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global collective about whom it is difficult to generalise since it is made up of a mixture 
of people including ‘biocurious’ amateurs, artists, ‘moonlighting’ working scientists, 
bioentrepreneurs and a few ‘hacker culture uber libertarians’ (Cowell, 2010).11  
 
The increased participation of non-institutional groups in biology can be interpreted as 
an expression of grassroots enthusiasm and distributed innovation, but it 
simultaneously gives rise to fears about ‘garage biology’, misuse and bioterrorism 
(Ledford, 2010). Making biology easier to engineer makes biology easier for everybody 
to engineer, and this could include those who have malicious intent. However, 
arguments are drawn, again, from software to maintain that it is not necessary to 
restrict access to synthetic biology. A famous quotation in open source software circles 
is Linus’ Law: “Given enough eyeballs, all bugs are shallow” (Raymond, 2000). Synthetic 
biologists rephrase this in their own terms: “our best potential defense against biological 
threats is to create and maintain open networks of researchers at every level, thereby 
magnifying the number of eyes and ears keeping track of what is going on in the world” 
(Carlson, 2010, p. 236). 
 
 
Motivations for commons-based approaches in synthetic biology 
 
The BioBricks strand of synthetic biology embraces openness and commons-based 
approaches, but when we disentangle the motivations behind this we see that they are 
diverse. One important motivation is pragmatic. The argument is that a commons-based 
regime will result in more innovation than a private one (Rai and Boyle, 2007), because 
the constructions of synthetic biology are likely to require many biological parts, so if 
each of these parts was patented this would lead to ‘patent thickets’ or ‘blocking patents’ 
(Oye and Wellhausen, 2009). If biological parts are freely available then this facilitates 
the development and commercialisation of downstream applications. Parallels can be 
drawn with the SNP consortium (Henkel and Maurer, 2009), where pharmaceutical 
companies clubbed together to ensure that very small genetic differences could not be 
patented (Holden, 2002). 
 
Such pragmatic motivations are often linked to more ‘ideological’ motivations, to 
promote “the cause of radical openness” (Kelty, 2005, p.199), which stretch beyond the 
purely economic. According to these motivations, openness is adopted because it is 
considered the best way to “benefit all people and the planet”.12 Ideological motivations 
also encompass the idea that as biological creatures, we have rights to access to the ‘stuff 
of life’. Endy (2010), for example, talks of ‘do it together’ biotechnology, and of how 
accessible technologies empower communities. 
 
The ideological and pragmatic motivations are often rolled together. As with the 
internet, both economic growth and greater democracy are hoped to emerge from open 
biology. Cohn (2005), referring to early discussions of synthetic biology, talks about how 
there were aspirations that “the hacker culture values like elegant design, creativity and 
sharing beneficial works of engineering for all, will spread to biology” (p.2). Here we see 
the desire not only to empower communities in a broad sense, but also to promote 
certain values such as elegant design and creativity. 
 
A contrasting interpretation of the push for commons-inspired approaches in synthetic 
biology is that this is merely a way of speeding up the development of a particular school 
of synthetic biology. This brings to light the important connections between openness 
                                                 
11 See http://diybio.org/ 
12 http://biobricks.org/ 
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and pressures for standardization. In order to establish common standards, which are 
needed for the BioBricks approach to progress, it is necessary for these standards to be 
open (Rai, 2009). If open parts are widely used then there will be investment in 
complementary parts, as part of a self-perpetuating cycle that will support the 
development of particular types of part, to the exclusion of others (Maurer, 2009). This 
‘interoperability’ is a requirement of a parts-based approach to synthetic biology, but it 
also raises the issue of possible anticompetitive behaviour, where one standard comes 
to dominate (Rai, 2009). 
 
Others argue, however, that the transparency provided by open access will be more 
likely to prevent the field from being monopolised and dominated by large corporations, 
as GM technology was by Monsanto (Cowell, 2010). This is connected to hopes that 
openness will lead to broader acceptance of synthetic biology. Carlson and Brent (2000), 
for example, say that they aim to “increase the number of citizens who have some 
sophistication on these issues and can participate in the political choices that increasing 
biological capacity can bring” (p.2). The idea of acceptance here is more than just the 
idea that the ‘general public’ will provide synthetic biologists with a mandate to pursue 
their specialised work. The aspirations go much deeper, with DIYbio advocates talking 
about how in the future parents will be able to re-programme food, and children will 
design synthetic pets (Dyson, 2007). This line of thought leads to discussion of what it 
means to be a good ‘biocitizen’ (Cowell, 2010) in a hoped for era of “democratization of 
biotechnology” (Billings and Endy, 2010, p.1). 
 
 
Open innovation 
 
As this discussion illustrates, the idea of ‘openness’ is a vague one which is interpreted 
in many different ways in parts-based approaches to synthetic biology. Following 
Johnson (2009), it is helpful to make distinctions between three different types of 
openness. ‘Open science’ is in the public domain, and outside the IP system. At the 
moment BioBricks are openly available in this manner from the Registry. ‘Open source’ 
depends on a particular IP system (copyright in the case of open source software), and 
this IP is mobilized, using particular licenses such as GNU and Unix, to enable certain 
legally-binding forms of access. ‘Open innovation’ is much broader, and it refers to a 
major global change in business models. Open innovation helps to contextualise both 
open science and open source, and it elucidates important features of BioBricks 
approaches to synthetic biology. 
 
Open innovation, sometimes called distributed innovation, is often described as being 
part of the shift we are witnessing from the industrial economy to the knowledge 
economy, where knowledge has allegedly become more important than land, labour or 
natural resources (Strathern, 2006; Council of the European Union, 2000). This shift is 
driven by globalisation and information technologies, and is accompanied by a 
movement from the centralised organisation of innovation to a recognition of the 
importance of distributed innovation. This type of innovation is more user-centred, and 
has the potential to redistribute agency, knowledge and power (Joly et al, 2010).13 
Although the paradigmatic example of distributed innovation is open source software, 
we also see distributed user-centred innovation in areas like mountain biking, 
snowboarding (Von Hippel, 2005), and participatory plant breeding (Joly et al, 2010). 
This type of innovation is often discussed by proponents of synthetic biology such as 
Carlson (2001), because it is seen to resonate with their objectives: 
 
                                                 
13 As Raymond (2000) points out, “Linux is subversive” (p.2). 
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It is already clear that distributed power generation will soon become more 
efficient than are centralized systems. Distributed manufacturing based upon local 
resources will save transportation costs, simplify customization, require less 
infrastructure investment, and, as a result, will likely cost less than centralized 
manufacturing. Distributed biological manufacturing is the future of the global 
economy. (p.17, emphasis added) 
 
Open innovation, particularly when tied to open source and open science, gives rise to 
social goals that are bold and ambitious. There is talk of “a rapid, radical reboot of the 
global innovation system for a truly free and open 21st century knowledge economy” 
(Open Science Summit, 2010). Economic arguments are made that old business models 
are unsustainable, and these arguments often refer to the extraordinary innovation of 
the internet (Lessig, 2001). Proponents of open innovation maintain that “the unchecked 
proliferation of intellectual property rights is perversely out of touch with, and 
downright inimical to, the collaborative, cumulative, and interdependent essence of 
innovation in the 21st century’s networked knowledge economy” (Jackson, 2010). 
 
Commentators argue that such moves towards openness are likely to have a disruptive 
effect on current thinking about business models, and that this could change the face of 
the existing biotechnology industry. Small companies could undermine existing 
platforms, displacing incumbent multinationals. In this way open innovation could be 
socially radical in its consequences, because of the redistribution of power that it could 
initiate. As Joly et al (2010) point out, where there is distributed innovation “there is a 
normative model of society being performed as well” (p.22).  
 
 
Future trajectories  
 
This normative model requires a legal framework, and in the last few years the BioBrick 
Public Agreement has been developed.14 This is a mechanism for facilitating access to 
and sharing of BioBricks.15 In its present version signing up to it gives contributors 
access to all the BioBricks in the Registry of Standard Biological Parts, although they 
must promise not to assert any existing or future property rights that they may hold on 
BioBricks.16 What is interesting about this agreement is that it is a contract, and does not 
follow the norms of open source software licenses, in that it is not ‘viral’. This means 
that contributors to the Registry are not obliged to share on the same terms anything 
that they take from the Registry and modify, that is, the Agreement “does not put any 
encumbrance on downstream uses, such as give-back or share-alike clause” (Smolke, 
2009, p. 1102). In this sense, the Registry is more similar to a public domain approach 
than a copyleft approach (Rai, 2009). Here we see that although synthetic biology is 
inspired by open source approaches, it diverges from them in important ways. 
 
Also, according to the agreement, parts can be patented if they are used to produce 
novel materials and applications.17 In this way, proprietary systems can be built on an 
open platform (Smolke, 2009). The explanation given for permitting patenting in certain 
                                                 
14 http://biobricks.org/bpa/users/agreement/ 
15 There are other suggestions about how to organize IP around BioBricks aside from the 
BioBrick Public Agreement (see Rai and Boyle, 2007), such as Henkel and Maurer’s (2009) 
suggestion of embedded Linux, where parts are shared after being kept private for six months 
(again, a direct borrowing from the software world). 
16 Those who contributed parts to the Registry could, however, request an attribution from users 
for future use of their part (http://biobricks.org/bpa/users/agreement/). 
17 http://biobricks.org/bpa/faq/#1 
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circumstances is that it will “[e]nable a rich, fully diverse ecology of commercial and 
public benefit use from the outset” (Endy, 2009, p. 11). This discussion of a ‘diverse 
ecology’ helps us understand how the JCVI’s proprietary work discussed above fits into 
the broader synthetic biology landscape. The idea is inspired by the rich ecosystem of 
software innovation which is regularly referred to approvingly in synthetic biology 
meetings (Orca, 2009). Synthetic biologists like to point out that in software the open 
source and the proprietary (sometimes referred to in terms of Stallman and Microsoft), 
happily coexist, and that Google, for example, has both an open source browser and 
closed search algorithms (Peterson, 2010). 
 
This parallel seems to work, in some circumstances, with the two different approaches 
to synthetic biology that I have focused on here. For example, one aim of the JCVI’s 
minimal genome work is to develop a chassis into which standardized biological parts 
can be put, and the genome assembly methods developed by JCVI have recently proved 
very useful for parts-based approaches (such as Gibson et al,  2009). It should also be 
noted that there are many different players in the synthetic biology field, beyond the 
two groups that I have broadly characterised here, and a range of different attitudes 
towards openness.18 
 
A difference between synthetic biology and software, however, is that software is a 
mature industry, and that Linux and other open source platforms only came into being 
after the technology was established (Bonaccorsi and Rossi, 2003). This raises the 
question of whether an attempt to impose a ‘diverse ecology’ on synthetic biology in its 
early stages will prove successful. Central to the idea of an ecology is that different forms 
of IP do not only coexist, but also contribute to each other’s mutual flourishing. But will 
this really be the case in synthetic biology? Some synthetic biologists think that we are 
not moving towards a diverse ecology, but towards a tipping point, where the field will 
either remain open (not just for the iGEM and DIYbio communities, but also for 
developing countries), or the IP will be locked up and commercialised for private benefit 
(Haseloff, 2010). 
 
There are several factors which may encourage us to conclude that synthetic biology is 
most likely to go down the more familiar path of previous biotechnologies. Powerful 
multinationals dominate the biotechnology field, and they would suffer from the 
creative destruction which is predicted to follow in the wake of open biology. Even small 
synthetic biology companies operate in an environment where they usually require 
venture capital, and as a result need to file patents to demonstrate that they are a good 
target for investment (Rai, 2009).19 And as I have shown above, there is a strong 
tradition of gene patenting in the biotechnology field that can be traced directly to the 
JCVI’s recent patent applications on synthetic genomes.  
 
It would be misleading to portray the patent system as immune to change. Even if 
patents become the dominant way of protecting synthetic biological inventions, they 
may start to reflect the extension of gene patenting to cover DNA in its informational 
form, and they may become more similar to software patents. Eisenberg (2000) argues 
that such developments would have to be closely scrutinised, since they would 
represent an illegitimate extension to the immaterial realm of a system originally 
                                                 
18 For example, companies such as Arymis Technologies and LS9 are filing patents, and parts 
registries are being developed by organisations such as the Joint Bioenergy Institute 
(http://www.jbei.org/fuels-synthesis/resources.shtml), and the Centre for Synthetic Biology and 
Innovation at Imperial College (http://www3.imperial.ac.uk/syntheticbiology). 
19 Ginkgo Bioworks, a synthetic biology company which decided not to pursue venture capital, is 
a notable exception. 
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designed to cover ‘bricks and mortar’ inventions. They take us far from the view that “[a] 
gene is a chemical compound, albeit a complex one”.20 
 
Although there are strong precedents which might encourage us to conclude that the 
patent path is the one that synthetic biology is most likely to take, we should not 
overlook the forces pulling in the other direction, toward open and distributed 
innovation. Synthetic biology may be the pressure point where dissatisfaction with the 
current system of IP protection in biotechnology comes to a head. As we saw above, one 
of the conclusions drawn from the iGEM competition is that the current system is 
broken and requires a fundamental overhaul. The increasingly broad range of actors 
participating in the life sciences – from engineers to computer scientists to 
undergraduates to citizen scientists and artists – may well have consequences for IP 
regimes.  
 
 
Conclusions 
 
The speculative nature of this discussion is indicative of the uncertainty involved in 
studying a field that is currently in the process of inventing itself and its ownership 
regimes. One of the most profound uncertainties at the heart of this discussion is the 
scientific and technical feasibility of the project of synthetic biology itself. The social and 
normative innovations being developed around BioBricks approaches to synthetic 
biology rely on the ability to make biological entities into standardized modular parts. 
But the field is continually being challenged by those who think that biology is simply 
too complicated to be standardized in this manner. A recent article called ‘Five hard 
truths for synthetic biology’ (Kwok, 2010) points to the unpredictability and unwieldy 
complexity of noisy biological systems, where context-dependence is crucial and where 
it is very hard to insulate parts of the system from each other, to such an extent that 
interactions may actually be more important than parts in biological systems.21 We saw 
above how similar issues arose in the work of the JCVI, because cellular context and a 
‘rich bacterial cultural medium’ are essential for synthetic genomes to work, weakening 
the assumption that DNA can be thought of as the ‘instructions for life’. Literature from 
philosophy and the social sciences also challenges the appropriateness of the application 
of informational and computational metaphors to living systems, and criticises this 
‘flattened’ understanding of the biological. 
 
This paper has argued, however, that the very same metaphors can be put to vastly 
different political and social purposes by different groups, and that they can underlie 
contrasting, sometimes even opposed, property regimes. We saw how informatic 
metaphors were recently drawn upon to argue against Myriad Genetics’ patents on 
breast cancer susceptibility genes. And in synthetic biology, proponents of open source 
inspired distributed innovation draw on these metaphors to assert the importance of 
the free availability of genetic information. But the same informational metaphors also 
expand the repertoire of ‘property talk’ for groups like JCVI who wish to extend IP 
protection in synthetic biology beyond the traditional grounds of ‘composition of 
matter’.   
 
This means that it is not sufficient for scholars of science and technology to simply 
critique the use of informational metaphors in synthetic biology. Instead it is necessary 
                                                 
20 Decision of the US Court of Appeals for the Federal Circuit, Amgen v. Chugai Pharmaceutical 
Co., 927 F.2d 1200. 
21 Synthetic biologists are keenly aware of these difficulties and are in fact heavily quoted in the 
Kwok article. 
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to be alive to their indeterminacy and examine the work that they are doing in different 
contexts. We should also not underestimate the performativity of these metaphors, or 
the potential for synthetic biologists to turn “tropes into worlds” (Haraway, 1994, p. 60). 
Whether or not these metaphors are appropriate ways of understanding existing 
biological systems, synthetic biologists are attempting to realise them in their biological 
creations. In other words, biology is becoming more like software because it is being 
engineered to be more like software.22 Whether synthetic biology will succeed in its 
objectives is an empirical question. If it does succeed, it may be necessary to rethink our 
current notions of the ‘biological’. 
 
I have shown that there are several different routes that ownership and sharing in 
synthetic biology could take, and which is followed will depend on the success of both 
technical and social innovations. It will be extremely interesting to see whether this field 
will follow the precedent set by gene patenting, whether a diverse ecology of the open 
and the proprietary will flourish, or whether the confluence of engineering, biology, 
software and community-building will lead to a participatory and distributed approach 
to innovation in synthetic biology. 
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